Of the 667 adult participants who are obese or overweight, those who received 50 milligrams of semaglutide “achieved a superior weight loss of 15.1 percent compared to a reduction of 2.4 percent with placebo, and 84.9 percent achieved a weight loss of 5 percent or more, compared to 25.8 percent with placebo,” drugmaker Novo Nordisk said May 22 in a news release.
If all people adhered to the treatment for 68 weeks, the average weight loss would be 17.4 percent, compared to the placebo’s 1.8 percent reduction.
Novo Nordisk said it plans to file for regulatory approval in 2023.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.